7754
AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy disease; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammato… Read more
7754 (7754) - Total Liabilities
Latest total liabilities as of June 2025: NT$273.48 Million TWD
Based on the latest financial reports, 7754 (7754) has total liabilities worth NT$273.48 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
7754 - Total Liabilities Trend (2021–2024)
This chart illustrates how 7754's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
7754 Competitors by Total Liabilities
The table below lists competitors of 7754 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Logwin AG
XETRA:TGHN
|
Germany | €384.45 Million |
|
Community Bank of the Bay
PINK:CBOBA
|
USA | $811.95 Million |
|
Unic Technology
TWO:5452
|
Taiwan | NT$1.66 Billion |
|
Clinica Baviera
MC:CBAV
|
Spain | €130.65 Million |
|
Stomil Sanok SA
WAR:SNK
|
Poland | zł645.99 Million |
|
LCY Technology Corp
TW:4989
|
Taiwan | NT$595.60 Million |
|
Resources Connection Inc
NASDAQ:RGP
|
USA | $94.69 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down 7754's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 7754's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 7754 (2021–2024)
The table below shows the annual total liabilities of 7754 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$339.90 Million | +20.13% |
| 2023-12-31 | NT$282.94 Million | +820.98% |
| 2022-12-31 | NT$30.72 Million | +87.25% |
| 2021-12-31 | NT$16.41 Million | -- |